Reports Q3 revenue $79.1M, consensus $79.13M. “Insmed made tremendous progress in the third quarter of 2023, punctuated by positive topline results from the ARISE study, encouraging blinded data from the Phase 2 trials of TPIP in PH-ILD and PAH, and the strongest quarter of ARIKAYCE revenues to date,” said Will Lewis, CEO. “Each of our mid- to late-stage pipeline assets continue to demonstrate strong performance in the clinic and Insmed’s enormous potential. We are extremely excited about the robust series of clinical, regulatory, and commercial catalysts that lie ahead as we strive to bring forward first-in-class or best-in-class medicines to patients in need.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INSM:
- Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update
- Insmed and Google Cloud partner for AI use in drug development
- Insmed (INSM) Q3 Earnings Cheat Sheet
- 5 Mid-Cap Stocks with Analyst Approval – October 2023
- Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call